Mergers and Acquisitions Overview - Kuehn Law, PLLC is investigating potential claims related to proposed mergers involving several companies, focusing on whether the boards acted to maximize shareholder value and disclosed material information [1][2] - ARCA Biopharma has entered a merger agreement with Oruka Therapeutics, with ARCA stockholders expected to own approximately 2.38% of the combined entity [1] - Squarespace, Inc. has agreed to sell to Permira, with shareholders set to receive $44.00 per share in cash upon transaction closure [1] - SouthState Corporation is acquiring Independent Bank Group Inc. in an all-stock transaction valued at approximately $2 billion, offering 0.60 shares of SouthState for each share of Independent Bank Group [2] - HMN Financial, Inc. will be acquired by Alerus Financial Corporation, with a share exchange ratio of 1.25 shares of Alerus for each share of HMN [2]

Group 1: Meme Stock Momentum - The resurgence of meme stocks, particularly GameStop (GME) and AMC Entertainment (AMC), was triggered by Keith Gill's return to social media, which was interpreted as a sign by the WallStreetBets community [1] - GameStop's sudden surge was accompanied by a broader rally in other high short interest stocks, with SunPower Corporation (SPWR) experiencing an 84% increase [2] Group 2: Short-Squeeze Stocks to Watch - Arca Biopharma (ABIO) has a high short interest of over 83% and a short squeeze score of 98.79, making it a notable candidate for potential short squeezes [3] - Rent the Runway (RENT) has seen its share prices double recently, driven by a strong earnings report, and has a short squeeze score of 97.73, with no shares available to short [5] - SilverSun Technologies (SSNT) has a short interest of 25% and a short squeeze score of 96.61, indicating it is also a significant candidate for short squeezes despite recent volatility [6]

Financial Performance - Cash and cash equivalents decreased to $35.9 million as of March 31, 2024, from $37.4 million as of December 31, 2023[8]. - Net loss for Q1 2024 was $2.0 million, or $0.14 per share, compared to a net loss of $1.3 million, or $0.09 per share, in Q1 2023[11]. - Total costs and expenses increased to $2,482,000 in Q1 2024, up from $1,796,000 in Q1 2023, representing a 38.2% increase[21]. - Net loss for Q1 2024 was $2,009,000, compared to a net loss of $1,346,000 in Q1 2023, reflecting a 48.9% increase in losses[21]. - Net loss per share for Q1 2024 was $(0.14), compared to $(0.09) in Q1 2023, indicating a 55.6% increase in loss per share[21]. - Interest and other income increased slightly to $473,000 in Q1 2024 from $450,000 in Q1 2023, a growth of 5.1%[21]. - The weighted average shares outstanding for basic and diluted shares increased to 14,501,143 in Q1 2024 from 14,410,143 in Q1 2023, an increase of 0.6%[21]. Expenses - General and administrative expenses increased to $2.3 million for Q1 2024, up from $1.4 million in Q1 2023, primarily due to a $1.1 million rise in professional fees related to the Merger Agreement[9]. - Research and development expenses were $0.2 million for Q1 2024, down from $0.4 million in Q1 2023, attributed to decreased headcount and the cessation of certain research grants[10]. - Total operating expenses for Q1 2024 were $2.5 million, compared to $1.8 million in Q1 2023[11]. - Research and development expenses decreased to $165,000 in Q1 2024 from $390,000 in Q1 2023, a reduction of 57.6%[21]. Strategic Developments - The Company has entered into a Merger Agreement with Oruka Therapeutics, which is subject to conditions and may significantly impact future operations[3][4]. - The Company expects to incur significant costs related to the exploration of strategic alternatives and the Merger, including legal and advisory fees[9]. - The Company believes its current cash will fund operations through mid-2025, but future viability depends on successful strategic transactions[8]. - The Company appointed Thomas Keuer as President and principal executive officer effective April 3, 2024[7]. Equity - Total stockholders' equity decreased to $35.1 million as of March 31, 2024, from $37.0 million as of December 31, 2023[20].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 000-22873 ARCA BIOPHARMA, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 36-3855489 (State or Other Jurisdiction of (I.R.S ...

ARCA biopharma and Oruka Therapeutics announce Merger AgreementARCA biopharma appoints Thomas Keuer as President WESTMINSTER, Colo., April 25, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), (the "Company") a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2024 financial results and provided a corporate update. In April 2022, ARCA established a Special Committee of the board o ...

NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies. Kuehn Law is investigating whether the Boards of the below companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process: Encore Wire Corporation (NASDAQ:WIRE) cli ...

Clinical-stage biopharmaceutical firm ARCA Biopharma (NASDAQ:ABIO) — which develops and commercializes cardiovascular disease therapies — saw its shares skyrocket during the midweek session. Earlier this morning, management announced a merger with Oruka Therapeutics, which ultimately aims to address chronic skin diseases. The large and expanding addressable market may bode well for ABIO stock, resulting in today’s big move.According to the official press release, the definitive agreement involves an all-sto ...

Follow Invezz on Telegram , Twitter , and Google News for instant updates >Arca Biopharma Inc (NASDAQ: ABIO) more than doubled on Wednesday after announcing a merger agreement with Oruka Therapeutics. Copy link to section The combined company following completion of the all-stock transaction will operate as Oruka Therapeutics and trade under “ORKA” on Nasdaq. Oruka – a biotech firm that focuses on novel biologics for skin diseases has already secured private financing worth $275 million to fund operations t ...

Merger to create a company focused on advancing Oruka's portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases Oruka, the third company founded based on assets generated by Paragon Therapeutics, expects to advance ORKA-001 and ORKA-002, potentially best-in-class antibodies targeting IL-23p19 and IL-17A/F, respectively, into clinical trials in 2025 Pre-closing private financing of approximately $275 million anticipated to fund operations through 2027 C ...

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Feb. 01, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2023 financial results and provided a corporate update. In April 2022, the Board of Directors established a Specia ...